SG11202111120VA - Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations - Google Patents

Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations

Info

Publication number
SG11202111120VA
SG11202111120VA SG11202111120VA SG11202111120VA SG11202111120VA SG 11202111120V A SG11202111120V A SG 11202111120VA SG 11202111120V A SG11202111120V A SG 11202111120VA SG 11202111120V A SG11202111120V A SG 11202111120VA SG 11202111120V A SG11202111120V A SG 11202111120VA
Authority
SG
Singapore
Prior art keywords
tyrosine kinase
kinase inhibitor
against cancer
compounds against
egfr mutations
Prior art date
Application number
SG11202111120VA
Inventor
Jacqulyne Robichaux
Monique Nilsson
John Heymach
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of SG11202111120VA publication Critical patent/SG11202111120VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202111120VA 2019-04-17 2020-04-16 Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations SG11202111120VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962835343P 2019-04-17 2019-04-17
PCT/US2020/028540 WO2020214824A1 (en) 2019-04-17 2020-04-16 Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations

Publications (1)

Publication Number Publication Date
SG11202111120VA true SG11202111120VA (en) 2021-11-29

Family

ID=72837936

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111120VA SG11202111120VA (en) 2019-04-17 2020-04-16 Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations

Country Status (12)

Country Link
US (1) US20220175779A1 (en)
EP (1) EP3956035A4 (en)
JP (1) JP2022529945A (en)
KR (1) KR20220004089A (en)
CN (1) CN113993592A (en)
AU (1) AU2020257395A1 (en)
BR (1) BR112021020601A2 (en)
CA (1) CA3132819A1 (en)
IL (1) IL287115A (en)
MX (1) MX2021012705A (en)
SG (1) SG11202111120VA (en)
WO (1) WO2020214824A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021016149A2 (en) 2019-02-26 2021-10-13 Janssen Biotech, Inc. COMBINATION THERAPIES AND STRATIFICATION OF PATIENTS WITH B-SPECIFIC ANTI-EGFR/C-MET ANTIBODIES
WO2020230091A1 (en) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
IL313670A (en) 2021-12-30 2024-08-01 Biomea Fusion Inc Pyrazine compounds as inhibitors of flt3
CN115998743B (en) * 2023-01-16 2024-05-28 威尚（上海）生物医药有限公司 Application of quinazoline compound in overcoming Oritinib resistance

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190125751A1 (en) * 2016-05-18 2019-05-02 Boehringer Ingelheim International Gmbh Anticancer combination therapy
CU20190051A7 (en) * 2016-11-17 2020-01-03 Univ Texas COMPOUNDS WITH ANTITUMOR ACTIVITY AGAINST CANCER CELLS THAT HAVE MUTATIONS IN EXON 20 OF EGFR OR HER2
WO2018213770A1 (en) * 2017-05-19 2018-11-22 Regents Of The University Of Minnesota Therapeutic methods
WO2019191279A2 (en) * 2018-03-27 2019-10-03 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
TW202019412A (en) * 2018-06-25 2020-06-01 美商光譜製藥公司 Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof
US20210346383A1 (en) * 2018-09-04 2021-11-11 Rain Therapeutics Inc. Compounds, compositions and methods for treating or preventing her-driven cancers
EP3946293A4 (en) * 2019-03-29 2023-05-03 Board of Regents, The University of Texas System Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions
BR112021019376A2 (en) * 2019-03-29 2021-12-07 Univ Texas Compounds with antitumor activity against cancer cells carrying her2 exon 21 insertions

Also Published As

Publication number Publication date
AU2020257395A1 (en) 2021-11-04
EP3956035A4 (en) 2023-01-25
US20220175779A1 (en) 2022-06-09
JP2022529945A (en) 2022-06-27
MX2021012705A (en) 2021-11-12
WO2020214824A1 (en) 2020-10-22
KR20220004089A (en) 2022-01-11
CN113993592A (en) 2022-01-28
EP3956035A1 (en) 2022-02-23
IL287115A (en) 2021-12-01
CA3132819A1 (en) 2020-10-22
BR112021020601A2 (en) 2021-12-07

Similar Documents

Publication Publication Date Title
IL287115A (en) Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations
EP3656769A4 (en) Aryl-phosphorus-oxygen compound as egfr kinase inhibitor
EP3399968B8 (en) Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
SG11202106435QA (en) Treating gastric cancer using ttfields combined with xelox or folfox
EP3648753A4 (en) Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
PL3533796T3 (en) Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
EP3955928A4 (en) Compounds with anti-tumor activity against cancer cells bearing tyrosine kinase inhibitor resistant egfr mutations
GB201808476D0 (en) Biomarkers for colorectal cancer
EP3567030A4 (en) Quinazoline compound for egfr inhibition
CY1123592T1 (en) AURORA A KINASE INHIBITOR
IL288522A (en) Egfr inhibitor for the treatment of cancer
SG11202112523UA (en) Detection of colorectal cancer
SG11202112522TA (en) Detection of colorectal cancer
IL314486A (en) Quinazoline pan-kras inhibitors
IL290561A (en) Alkynyl quinazoline compounds
EP3852762A4 (en) Novel quinazoline egfr inhibitors
EP3523285A4 (en) Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors
IL286727A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
SG11202104609SA (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
ZA202108775B (en) New egfr inhibitors
EP3986565C0 (en) New egfr inhibitors
EP3604312A4 (en) Fourth-generation egfr tyrosine kinase inhibitor
SG10201909596RA (en) Synthesis of Tyrosine Kinase Inhibitors
GB201909468D0 (en) Compounds for treating cancer
EP3930837A4 (en) Quinazolinone compounds